01 / Mechanism

What it actually does.

Liraglutide is a synthetic GLP-1 (glucagon-like peptide-1) analog with two modifications: substitution of arginine for lysine at position 34 and addition of a C16 palmitic-acid side chain at position 26. The fatty-acid chain promotes reversible binding to serum albumin, which extends the half-life from native GLP-1's ~2 minutes to ~13 hours — enough for once-daily dosing but not for weekly [Knudsen 2000].

At the receptor, liraglutide is a full GLP-1 agonist with the standard downstream effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction via direct hypothalamic and brainstem signaling. The cardiovascular benefit demonstrated in LEADER appears to be driven by anti-atherogenic effects on endothelium and macrophage inflammatory tone rather than glucose lowering itself [Marso 2016].

Compared to semaglutide's weekly schedule and ~165-hour half-life, liraglutide's daily dosing produces lower peak concentrations and more pharmacological flexibility — easier to pause, faster to wash out, and arguably easier to tolerate through titration in GI-sensitive patients.

02 / Dosing

Standard titration schedule.

Week	Subcutaneous dose	Indication / brand	Note
1	0.6 mg daily	Initiation	Not therapeutic — tolerance dose
2	1.2 mg daily	T2D (Victoza low)	First glycemic effect
3+	1.8 mg daily	T2D maintenance (Victoza)	LEADER trial dose
4	2.4 mg daily	Obesity titration (Saxenda)	Continue weekly steps
5+	3.0 mg daily	Obesity maintenance (Saxenda)	SCALE trial target
Pediatric ≥12 y	0.6 → 3.0 mg daily	Saxenda adolescent	BMI ≥95th percentile + weight ≥60 kg

Efficacy expectations

SCALE 1839 trial at 56 weeks: −8.0% body weight with Saxenda 3.0 mg vs −2.6% with placebo. That's roughly half what semaglutide 2.4 mg delivers in STEP and a third of what tirzepatide 15 mg achieves in SURMOUNT. Liraglutide is not the answer if maximum weight loss is the goal — it's the answer when daily titration tolerability or pediatric labeling matters.

03 / Contraindications

Who should not take this.

Personal or family history of medullary thyroid carcinoma (MTC). FDA black-box warning across the GLP-1 class.
Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same rationale.
Prior pancreatitis. Relative contraindication; pancreatitis is a labelled adverse event.
Severe gastroparesis. Exacerbates underlying motility.
Pregnancy. Discontinue if pregnancy is detected.
Severe gallbladder disease. Cholelithiasis risk with rapid weight loss.

04 / Side effects

What to expect.

Nausea (~39%). Class typical; usually dose-dependent and tachyphylactic over weeks.
Diarrhea (~21%), constipation (~19%). Same as the weekly GLP-1s.
Injection-site reactions. More common than with weekly agents because there are 7× more injections per month.
Headache, dizziness, fatigue. Often related to early caloric deficit; usually settle.
Hypoglycemia. Low risk as monotherapy; higher in combination with sulfonylureas or insulin.
Gallstones. Class-effect; rises with rapid weight loss.
Rare: pancreatitis, MTC (preclinical signal only in humans).

05 / Where it still fits

Niche, but a real one.

With semaglutide and tirzepatide dominating weight outcomes, why use a daily, less-potent first-generation GLP-1 in 2026? Four legitimate reasons:

Titration intolerance. Patients who can't tolerate weekly GLP-1s often manage daily dosing better because the peak-to-trough swing is smaller. A daily 0.6 mg dose simply isn't equivalent to even the lowest weekly semaglutide step.
Pediatric obesity. Saxenda was the first GLP-1 approved for adolescents 12+ in 2020, based on the trial of 251 youth showing significant BMI reduction [Kelly 2020]. Semaglutide pediatric approval came later; tirzepatide pediatric labeling is still pending.
Hepatic comorbidity. The shorter half-life is an asset when liver disease or unstable polypharmacy makes a long-washout drug risky.
Cardiovascular evidence in T2D. LEADER's 13% MACE reduction (HR 0.87) remains a hard-endpoint outcome cited in ADA/EASD guidelines for patients with established atherosclerotic disease [Marso 2016].

For the broader landscape — how liraglutide fits inside the GLP-1 family — see the long read on the GLP-1 era.

06 / Cost

Honest pricing.

Source	Form	~Monthly cost (USD)	Note
Brand	Saxenda pen (insurance)	$25–$100 copay	If covered
Brand	Saxenda pen (cash)	$1,300+	List price
Brand	Victoza pen (cash)	$900+	T2D label only
Generic liraglutide	Hikma authorized generic (2024+)	$200–$500	Recently launched

Liraglutide's patent expired in 2023 and authorized generics began appearing in 2024, opening a meaningful price gap below the weekly branded agents. For cost-sensitive patients who can tolerate daily injection, generic liraglutide is now a real consideration.

07 / Key references

The evidence base.

Knudsen LB et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664–1669. [Knudsen 2000]
Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM. 2016;375(4):311–322. [Marso 2016]
Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity & Prediabetes). NEJM. 2015;373(1):11–22. [Pi-Sunyer 2015]
Davies MJ et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687–699. [Davies 2015]
Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. NEJM. 2020;382(22):2117–2128. [Kelly 2020]
Mehta A et al. Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice. 2017;3(1):3–14. [Mehta 2017]

About this profile

Last reviewed against evidence: 2026-05-12. This profile is editorial reference content, not sponsored. Wellness Radar does not run affiliate links on prescription drugs. Decisions about liraglutide belong to you and a clinician who knows your full medical history.

Liraglutide